Article info
PDFClinical and epidemiological research
Concise report
Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials
- Correspondence to Dr Matthieu Roustit, Unité de Pharmacologie Clinique, Centre d'Investigation Clinique de Grenoble—Inserm CIC03, CHU de Grenoble, 38043 Grenoble Cedex 09, France; MRoustit{at}chu-grenoble.fr
Citation
Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials
Publication history
- Received October 16, 2012
- Revised January 9, 2013
- Accepted February 3, 2013
- First published February 20, 2013.
Online issue publication
May 01, 2023
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions